List of Excipients in Branded Drug CLOBETASOL PROPIONATE (EMOLLIENT)

Generic Drugs Containing CLOBETASOL PROPIONATE (EMOLLIENT)

Company	Ingredient	NDC	Excipient
E Fougera & Co a division of Fougera Pharmaceuticals Inc	clobetasol propionate	0168-0301	CETOSTEARYL ALCOHOL
E Fougera & Co a division of Fougera Pharmaceuticals Inc	clobetasol propionate	0168-0301	CITRIC ACID MONOHYDRATE
E Fougera & Co a division of Fougera Pharmaceuticals Inc	clobetasol propionate	0168-0301	DIMETHICONE 350
E Fougera & Co a division of Fougera Pharmaceuticals Inc	clobetasol propionate	0168-0301	IMIDUREA
E Fougera & Co a division of Fougera Pharmaceuticals Inc	clobetasol propionate	0168-0301	ISOPROPYL MYRISTATE
E Fougera & Co a division of Fougera Pharmaceuticals Inc	clobetasol propionate	0168-0301	POLYOXYL 20 CETOSTEARYL ETHER

What are the Most Frequently-Used Excipients in CLOBETASOL PROPIONATE (EMOLLIENT)?

# Of NDCs	Excipient
4	CETETH-20
5	CETOSTEARYL ALCOHOL
5	CITRIC ACID MONOHYDRATE
1	DIMETHICONE
4	DIMETHICONE 350
4	IMIDUREA

Clobetasol Propionate Emollient Excipient Strategy, Patent Landscape, and Commercial Opportunities

Last updated: September 3, 2026

Clobetasol propionate 0.05% emollient cream is a high-potency topical corticosteroid product in a mature generic market. The active-ingredient estate is no longer the principal barrier to entry. Commercial differentiation depends on vehicle performance, tolerability, packaging, patient adherence, supply reliability, and evidence supporting bioequivalence or therapeutic equivalence.

The strongest opportunities are premium generic emollient creams, preservative-minimized products, improved dispensing systems, and differentiated vehicles that maintain clobetasol delivery while reducing irritation and mess. Patent risk is concentrated in specific formulations, delivery systems, and method-of-use claims rather than in clobetasol propionate itself.

What is clobetasol propionate emollient cream?

Clobetasol propionate emollient cream is a prescription topical corticosteroid containing clobetasol propionate at a concentration of 0.05%. It is indicated for short-term treatment of corticosteroid-responsive dermatoses, including moderate-to-severe plaque psoriasis and other inflammatory skin conditions.

Clobetasol is classified as a super-high-potency, or Class I, topical corticosteroid in U.S. dermatology references. Treatment duration and treated body-surface area are restricted because prolonged or extensive use can increase the risk of hypothalamic-pituitary-adrenal axis suppression, skin atrophy, and systemic corticosteroid exposure.[1]

The term "emollient" generally identifies the cream vehicle rather than a separate active ingredient. The vehicle is designed to soften and hydrate the stratum corneum, improve spreadability, and support delivery of clobetasol into inflamed skin.

What excipients are used in clobetasol propionate emollient cream?

A representative clobetasol propionate emollient cream uses a conventional oil-in-water or water-containing emollient system. The approved Temovate E formulation lists excipients including cetostearyl alcohol, chlorocresol, citric acid, glyceryl stearate, isopropyl myristate, propylene glycol, purified water, sodium citrate, and stearyl alcohol.[2]

Excipient or excipient class	Functional role	Commercial relevance
Cetostearyl alcohol	Consistency agent, co-emulsifier, emollient	Controls viscosity and cream body
Stearyl alcohol	Emollient and structuring agent	Supports semisolid stability and skin feel
Glyceryl stearate	Emulsifier and emollient	Helps form and stabilize the cream matrix
Isopropyl myristate	Emollient and penetration-supporting solvent	Improves spreadability and sensory profile
Propylene glycol	Humectant and solvent	Supports hydration and active distribution; may irritate sensitive skin
Chlorocresol	Preservative	Controls microbial growth; creates preservative-sensitivity considerations
Citric acid and sodium citrate	Buffer system	Controls pH and supports chemical stability
Purified water	Continuous-phase solvent	Determines hydration, rheology, and microbial-control requirements

The reference formulation is not automatically the optimal commercial formulation. A generic manufacturer can pursue Q1/Q2 sameness, a closely comparable vehicle, or a differentiated formulation route. Each choice changes development cost, regulatory risk, patent exposure, and consumer positioning.

How should an excipient strategy be designed for clobetasol emollient products?

The primary formulation objective is to achieve consistent clobetasol delivery without increasing irritation, instability, or manufacturing complexity.

Emollient selection and skin feel

Isopropyl myristate, fatty alcohols, glyceryl esters, hydrocarbons, silicones, and ester-based emollients can produce materially different after-feel and spreading characteristics. A heavy, occlusive cream can improve hydration but may reduce patient acceptance on hairy areas, intertriginous sites, or large lesions.

A lighter cream may improve adherence but can reduce occlusivity and alter drug partitioning into the stratum corneum. The commercial target should be defined by treatment site:

• Dry plaques may benefit from higher occlusivity and richer emollience.
• Scalp and hair-bearing areas require low-residue delivery.
• Flexural areas require lower irritation and reduced occlusion.
• Hand and foot psoriasis may justify a higher-viscosity cream or ointment.
• Pediatric and elderly populations may favor low-sting, low-fragrance, easily spreadable systems.

Humectant strategy

Propylene glycol is common in topical products because it acts as a solvent and humectant. It can also cause irritation or allergic contact dermatitis in susceptible users. A product designed for sensitive skin could reduce or replace propylene glycol with glycerin, sorbitol, pentylene glycol, or other humectant systems.

Any substitution must be evaluated for clobetasol solubility, particle-size behavior, preservative performance, water activity, viscosity, and in vitro release. The excipient change can affect dermal permeation even when the drug concentration remains unchanged.

Preservative strategy

Chlorocresol provides antimicrobial protection but may limit positioning for users seeking preservative-minimized products. Alternatives include phenoxyethanol, parabens, organic-acid systems, benzyl alcohol, or reduced-water formulations. Each option creates a different irritation and regulatory profile.

A preservative-free product is technically more difficult for a conventional multidose cream. It may require:

• An airless pump
• Unit-dose packaging
• A lower-water or anhydrous vehicle
• Validated microbiological controls
• Extractables and leachables assessment
• Container-closure integrity testing

Preservative reduction is commercially attractive only if the packaging system prevents contamination and the product remains stable throughout in-use testing.

pH and buffer design

The pH should support clobetasol chemical stability, preservative efficacy, and skin tolerability. Citric acid and citrate buffers are suitable for mildly acidic topical systems, but the final pH must be validated after scale-up and throughout shelf life.

Changes in pH can alter emulsion stability, preservative activity, drug solubility, and the ionization state of formulation components. A buffer is therefore a performance-critical excipient, not a passive manufacturing ingredient.

Rheology and particle control

Clobetasol propionate is a potent drug used at a low concentration. Small changes in particle size, crystal form, aggregation, or distribution can affect dose uniformity and release. The formulation should control:

• Drug particle-size distribution
• Microscopic uniformity
• Cream viscosity across shear rates
• Spreadability
• In vitro release rate
• Water loss and evaporation
• Phase separation
• Tube or pump delivery performance

For topical semisolids, comparative quality analysis should include Q1 composition, Q2 quantitative composition, and Q3 microstructure. Q3 attributes include globule size, rheology, pH, thermal behavior, polymorphism, and other product-specific characteristics.[3]

What FDA regulatory pathway applies to clobetasol propionate emollient cream?

Most conventional generic clobetasol propionate creams are developed through the abbreviated new drug application, or ANDA, pathway. The applicant must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements.

For topical products, the regulatory burden is not limited to matching the active ingredient and strength. FDA evaluates the formulation, dosage form, route of administration, performance, impurities, microbial quality, and evidence supporting equivalence. FDA product-specific guidances and topical dermatological product guidance influence study design.[3,4]

A materially different formulation may require a 505(b)(2) application rather than an ANDA, particularly when the sponsor relies on clinical or pharmacologic information beyond the reference product. That route can support innovation but carries higher development cost and potentially greater patent-certification exposure.

FDA status and dosage forms

Clobetasol propionate has been marketed in multiple topical forms, including:

Dosage form	Typical commercial rationale
Emollient cream	Dry, inflamed plaques; broad generic opportunity
Ointment	Maximum occlusion for thick plaques
Lotion	Scalp and hair-bearing areas
Solution	Scalp and localized application
Gel	Non-greasy delivery and targeted application
Foam	Rapid spreading and improved cosmetic acceptability
Shampoo	Scalp psoriasis and short-contact treatment
Spray	Convenient application over larger areas

FDA-approved products and labeling vary by formulation, indication, treatment duration, and application instructions. A sponsor cannot assume that evidence for one clobetasol dosage form transfers to another.

What patents protect clobetasol propionate emollient products?

The basic clobetasol propionate compound and early conventional topical formulations are mature technologies. Their foundational patent protection has expired in the United States. Current patent risk is more likely to arise from formulation-specific, packaging-specific, delivery-specific, or method-of-use claims.

Potential claim categories include:

1. Vehicle composition claims covering defined emulsion components, ratios, solvents, emollients, or preservative systems.
2. Particle and microstructure claims covering drug crystal size, dispersed-phase dimensions, or rheological parameters.
3. Delivery-system claims covering pumps, sprays, foams, metered-dose containers, or contamination-resistant packaging.
4. Method-of-use claims covering treatment duration, application frequency, body site, or treatment of a defined patient population.
5. Combination claims covering clobetasol with keratolytics, moisturizers, antimicrobials, or other dermatologic actives.
6. Manufacturing claims covering homogenization, crystallization, particle-size reduction, or process controls.

A patent search should distinguish between patents listed in the FDA Orange Book and unlisted patent rights. Approved drug products with active ingredients in conventional topical formulations may have limited or no Orange Book-listed patents, while separate formulation or delivery products can have relevant listings or unlisted patents.[5]

What is the Orange Book status of clobetasol propionate emollient cream?

Orange Book analysis must be performed at the specific reference-listed drug and dosage-form level. "Clobetasol propionate" is not a single Orange Book asset. Cream, ointment, lotion, foam, shampoo, gel, solution, and spray products can have different reference products, sponsors, indications, and patent records.

The key commercial questions are:

Orange Book issue	Commercial effect
Reference-listed drug identification	Determines the ANDA reference product
Listed patents	Determines patent certification obligations
Pediatric exclusivity	Can delay approval or affect patent timing
Three-year exclusivity	May restrict certain applications for a new formulation or indication
Orphan exclusivity	Generally not central to standard clobetasol cream
Paragraph IV certification	Can trigger patent litigation and a 30-month stay
First-filer status	May create 180-day generic exclusivity in qualifying cases

The relevant Orange Book entry should be checked for the exact clobetasol propionate emollient cream reference product before filing or acquisition decisions.[5]

When does clobetasol propionate emollient lose exclusivity?

The foundational exclusivity period for conventional clobetasol propionate cream has passed. Generic entry is already established across several topical dosage forms. The commercial question is therefore not whether the active ingredient has generic competition, but whether a particular product retains protection through a differentiated formulation, indication, device, or delivery platform.

A new clobetasol product can create a fresh exclusivity profile through:

• A novel formulation approved under 505(b)(2)
• A new indication
• A new dosage form
• A pediatric indication
• A qualifying clinical investigation supporting a new approval
• A patentable delivery or packaging system

Any new exclusivity is product-specific and does not restore exclusivity to conventional clobetasol cream.

Are Paragraph IV challenges relevant to clobetasol emollient cream?

Paragraph IV litigation is relevant when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or not infringed. For a mature clobetasol cream, the probability of major compound-patent litigation is low. Risk can remain for newer foam, spray, shampoo, gel, or formulation products with active patents.

A Paragraph IV strategy should examine:

• Whether the patent is listed for the exact reference product
• Whether the ANDA formulation practices every asserted claim
• Whether a design-around avoids claimed excipients or ratios
• Whether the patent claims a method of use that the proposed label will include
• Whether the patent expires before commercial launch
• Whether a 30-month stay would materially delay approval

Patent risk is usually lower for a conventional emollient cream that uses established excipients and avoids protected delivery architecture.

What formulation patents and manufacturing barriers affect commercial entry?

The main manufacturing barriers are process consistency and topical bioequivalence, not raw-material scarcity. Clobetasol propionate is commercially available from multiple pharmaceutical ingredient suppliers, but supplier qualification must address potency, impurities, particle morphology, polymorphism, residual solvents, and microbiological quality.

Manufacturing scale-up risks include:

• Nonuniform dispersion of low-dose clobetasol
• Changes in homogenization energy
• Drug recrystallization during cooling
• Batch-to-batch viscosity variation
• Preservative underperformance
• Tube filling variability
• Drug adsorption to manufacturing equipment
• Stability changes after packaging
• In-use contamination

Process patents may be avoidable through conventional mixing, emulsification, and filling operations. Trade secrets related to scale-up, particle engineering, or analytical methods may still create practical barriers even when no blocking patent exists.

What commercial opportunities exist for clobetasol propionate emollient products?

The largest opportunities are in product usability and differentiated access rather than new pharmacology.

Premium generic cream

A manufacturer can position a cream around low residue, rapid absorption, smooth spreadability, or reduced sting. This strategy is most credible when supported by comparative rheology, in vitro release, stability, and patient-use data.

Preservative-minimized or preservative-free product

Sensitive-skin positioning can support a higher price, but the packaging and microbiological-control system must justify the formulation. An airless pump or unit-dose package can create device and manufacturing differentiation.

Site-specific delivery

A portfolio can use different vehicles for distinct treatment sites:

• Rich emollient cream for dry plaques
• Lotion or solution for scalp disease
• Foam for rapid application and cosmetic acceptability
• Ointment for thick, highly keratotic lesions
• Shampoo for short-contact scalp treatment

Combination products

Clobetasol may be combined with agents such as salicylic acid or moisturization-supporting components. Combination products can improve lesion penetration or scale removal but raise irritation, stability, labeling, and regulatory complexity.

Packaging innovation

Packaging can improve dose control and adherence through metered pumps, narrow-orifice tubes, applicator tips, or contamination-resistant systems. A device-centered strategy may support patent filings and 505(b)(2) development, particularly if the packaging materially changes dosing or usability.

How strong is the patent estate for clobetasol propionate emollient cream?

The conventional clobetasol emollient cream patent estate is weak relative to newer topical delivery products because the active ingredient, concentration, and basic cream technology are mature. The strongest protectable positions are narrow and product-specific.

Asset category	Relative strength
Clobetasol propionate active ingredient	Low; mature and widely genericized
Conventional 0.05% cream	Low to moderate, depending on formulation claims
Novel excipient system	Moderate if composition and performance are distinct
Preservative-free package	Moderate if device and formulation claims are well drafted
Foam, spray, or metered delivery	Moderate to strong for specific products
New indication or dosing regimen	Moderate, subject to method-of-use validity
Manufacturing process	Moderate if process produces a measurable product advantage

A sponsor should not rely on a broad claim to "clobetasol in an emollient vehicle." Such claims face novelty, obviousness, enablement, and written-description challenges. Narrow claims linked to measurable product attributes, defined excipient ranges, and demonstrated performance are more defensible.

What generic launch scenarios exist for clobetasol emollient cream?

Three launch models are commercially plausible.

Standard ANDA launch

The applicant matches the reference composition or uses a formulation accepted as equivalent. This approach minimizes clinical cost and accelerates approval but exposes the product to price competition.

Differentiated ANDA or device-supported product

The sponsor retains the generic pathway while improving packaging, sensory properties, or preservative strategy. The product may command better payer or pharmacy positioning if the differentiation is meaningful.

505(b)(2) reformulation

The sponsor develops a materially distinct cream, foam, spray, or combination product. This route supports stronger branding and potentially new patent rights but requires greater investment and may face clinical, patent, and reimbursement hurdles.

How does clobetasol emollient compare with competing topical corticosteroids?

Clobetasol is among the most potent topical corticosteroids. Competitors include betamethasone dipropionate, fluocinonide, halobetasol propionate, mometasone furoate, and triamcinolone acetonide.

Product characteristic	Clobetasol propionate 0.05%	High-potency alternatives
Potency	Super-high potency	Ranges from medium to super-high
Typical use	Severe localized inflammatory dermatoses	Site- and disease-dependent
Treatment duration	Generally short term	Varies by product and potency
Vehicle opportunity	High across cream, foam, lotion, ointment, and shampoo	Also high, with different competitive profiles
Generic competition	Extensive	Extensive
Differentiation basis	Vehicle, adherence, packaging, formulation	Vehicle, safety profile, indication, and convenience

A clobetasol product competes less on molecular novelty than on prescriber familiarity, pharmacy availability, patient tolerability, and total treatment cost.

Key Takeaways

• Clobetasol propionate 0.05% emollient cream is a mature prescription generic product.
• The active ingredient does not provide a meaningful new-entry barrier.
• The main formulation levers are emollient choice, humectant selection, preservative system, pH, rheology, particle control, and packaging.
• Preservative-minimized, low-irritancy, airless-pump, and site-specific products offer the clearest commercial differentiation.
• Conventional products generally fit the ANDA pathway; materially different formulations may require 505(b)(2) development.
• Patent risk is concentrated in novel vehicles, delivery systems, methods of use, and manufacturing processes.
• Orange Book analysis must be conducted against the exact reference-listed drug and dosage form.
• Generic launch economics are likely to be driven by manufacturing efficiency, channel access, supply reliability, and product usability rather than compound exclusivity.
• No biosimilar pathway applies because clobetasol propionate is a small-molecule drug, not a biologic.
• A defensible patent estate should claim specific excipient ranges, microstructure, device architecture, or measurable performance attributes.

FAQs About Clobetasol Propionate Emollient Commercial Strategy

Can propylene glycol be removed from clobetasol emollient cream?

Yes. Propylene glycol can be replaced or reduced, but the sponsor must revalidate clobetasol solubility, release, permeation, preservative efficacy, stability, and skin tolerability.

Is a preservative-free clobetasol cream commercially feasible?

Yes, but multidose packaging creates microbiological-control challenges. Airless pumps, unit-dose formats, or low-water systems are the most practical routes.

Does a different excipient automatically require a 505(b)(2) application?

No. A formulation can qualify for an ANDA if it meets applicable sameness and equivalence requirements. A materially different product that cannot meet ANDA requirements may require 505(b)(2) development.

Can a clobetasol cream patent cover all generic versions?

Broad coverage is unlikely for mature conventional cream technology. Enforceability depends on the exact claim language, formulation composition, product characteristics, and whether the generic practices each claim limitation.

Is clobetasol propionate suitable for an OTC product?

Standard clobetasol products are prescription products because of their potency, risks, treatment restrictions, and need for medical diagnosis. An OTC strategy would require a separate FDA regulatory basis and is not a routine line extension.

References

1. U.S. Food and Drug Administration. (2024). Clobetasol propionate cream prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2024). Temovate E emollient cream prescribing information. FDA-approved labeling.

3. U.S. Food and Drug Administration. (2022). Topical dermatological drug products that are combinations of active ingredients and/or contain permeation enhancers: Guidance for industry. FDA.

4. U.S. Food and Drug Administration. (2023). Product-specific guidances for generic drug development. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.